REATA PHARMACEUTICALS CEO J Huff's 2021 pay falls 37% to $4M
REATA PHARMACEUTICALS reports 2021 executive compensation
By ExecPay News
Published: April 29, 2022
REATA PHARMACEUTICALS reported fiscal year 2021 executive compensation information on April 29, 2022.
In 2021, five executives at REATA PHARMACEUTICALS received on average a compensation package of $2.6M, a 42% decrease compared to previous year.
Average pay of disclosed executives at REATA PHARMACEUTICALS
J. Warren Huff, Chief Executive Officer, received $4M in total, which decreased by 37% compared to 2020. 84% of Huff's compensation, or $3.4M, was in option awards. Huff also received $636K in salary and $6K in other compensation.
For fiscal year 2021, the median employee pay was $244,581 at REATA PHARMACEUTICALS. Therefore, the ratio of J. Warren Huff's pay to the median employee pay was 16 to one.
Manmeet S. Soni, Chief Financial Officer, received a compensation package of $3M, which decreased by 33% compared to previous year. 61% of the compensation package, or $1.8M, was in option awards.
Colin J. Meyer, Chief Innovation Officer and Executive Vice President, earned $2.6M in 2021, a 39% decrease compared to previous year.
Dawn C. Bir, Chief Commercial Officer and Executive Vice President, received $1.8M in 2021, which decreases by 53% compared to 2020.
Michael D. Wortley, Chief Legal Officer, earned $1.8M in 2021, a 54% decrease compared to previous year.
Related executives
J Huff
REATA PHARMACEUTICALS
Chief Executive Officer
Manmeet Soni
REATA PHARMACEUTICALS
Chief Financial Officer
Dawn Bir
REATA PHARMACEUTICALS
Chief Commercial Officer and Executive Vice President
Colin Meyer
REATA PHARMACEUTICALS
Chief Innovation Officer and Executive Vice President
Michael Wortley
REATA PHARMACEUTICALS
Chief Legal Officer
You may also like
Source: SEC filing on April 29, 2022.